Welcome to our dedicated page for TENET HEALTHCARE SEC filings (Ticker: THC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Tenet Healthcare Corporation filings document the regulatory record of a healthcare services company with hospital operations, an ambulatory surgery platform and Conifer revenue cycle management services. Its 8-K reports disclose operating results, financial outlook updates, Regulation FD information, material agreements involving Conifer, and debt financing matters tied to senior secured first lien notes and senior notes.
Tenet's proxy and current reports also cover board composition, shareholder voting matters, executive compensation, officer transition agreements, controller and principal accounting officer appointments, equity-award terms, common stock, senior-note securities and related governance disclosures. These filings connect THC's capital structure and management oversight to its Ambulatory, Hospital and Conifer business activities.
Tenet Healthcare (THC) director J. Robert Kerrey reported a charitable transfer of company stock. On 10/29/2025, he disposed of 971 shares of common stock under transaction code G at $0. Following the transaction, he beneficially owns 21,406 shares, held directly. The filing notes the shares were contributed to the Fidelity Charitable Gift Fund.
THC received a Form 144 notice for a proposed sale of restricted common stock. The notice covers 2,500 shares with an aggregate market value of $521,075.25, to be sold through Fidelity Brokerage Services on or about 10/29/2025 on the NYSE.
The seller acquired these shares on 05/09/2025 via restricted stock vesting from the issuer as compensation. Shares outstanding are listed as 87,885,000; this is a baseline figure, not the amount being sold.
Tenet Healthcare (THC) reported Q3 2025 results. Net operating revenues were $5,289 million versus $5,126 million a year ago. Operating income was $889 million. Net income available to common shareholders was $342 million, with diluted EPS of $3.86.
Ambulatory Care continued to expand, generating $1,275 million in net operating revenues in the quarter, up from $1,139 million. For the first nine months, operating cash flow reached $2,809 million, supporting capital spending and equity returns. The company repurchased 7,828 thousand shares year‑to‑date at an average price of $151.75, and the board increased the 2024 share repurchase program in July; $1,688 million remained authorized at September 30.
Cash and cash equivalents were $2,975 million, and long‑term debt (net of current portion) was $13,102 million. As of October 22, 2025, shares outstanding were 87,885 thousand. Tenet highlighted a new FASB practical expedient (ASU 2025‑05) it is evaluating and noted U.S. tax law changes enacted in July 2025 that reduce taxable income through bonus depreciation and interest deduction adjustments.
Tenet Healthcare Corporation furnished a Form 8-K under Item 2.02 to announce it issued a press release with financial results for the quarter ended September 30, 2025. The company attached the release as Exhibit 99.1 and incorporated it by reference.
The information was furnished, not filed, under the Exchange Act. Tenet lists its securities as common stock (THC) and 6.875% Senior Notes due 2031 (THC31).
Saumya Sutaria, identified as both a director and the CEO of Tenet Healthcare Corp (THC), reported the sale of common stock on 09/10/2025. The Form 4 discloses two separate sale transactions: 59,456 shares sold at a weighted average price of $190.48 (prices ranged $190.14–$191.05) and 19,306 shares sold at a weighted average price of $191.70 (prices ranged $191.18–$192.06), for a total of 78,762 shares sold. Following the reported transactions, beneficial ownership is reported as 387,989 shares after the first set of sales and 368,683 shares after the second set. The Form 4 is dated and signed on behalf of Ms. Sutaria by an attorney-in-fact, Chad J. Wiener, on 09/12/2025. The filing includes undertakings to provide breakouts of shares sold at each price upon request.
Form 144 notice for proposed sale of securities. The filing reports an intended sale of 78,762 shares of Common stock through Fidelity Brokerage Services LLC on or about 09/10/2025 with an aggregate market value of $15,025,892.48. The shares were acquired on 08/31/2025 via restricted stock vesting from the issuer and the payment type is listed as compensation. The filing states there were no securities sold in the past three months. Several issuer identification fields (including the issuer name and SEC file number) are not populated in the provided content.
Saumya Sutaria, CEO and director of Tenet Healthcare Corporation (THC), reported vesting and related transactions on 08/29/2025. A grant of 53,341 time-based restricted stock units from 2021 vested in full and converted one-for-one into 53,341 shares. Following the vesting and subsequent share transfers to cover taxes and other dispositions, the filing shows Sutaria beneficially owned 447,445 shares.
The filing records shares withheld for taxes: 27,087 shares withheld upon vesting and 54,174 shares delivered to satisfy withholding for performance share units. The report states a reported disposition of 53,341 shares under transaction code M for the conversion event and lists a closing stock price of $184.33 used in the withholding calculation.
Insider sale disclosed: Tenet Healthcare director Christopher S. Lynch reported a sale of 12,350 shares of Tenet Healthcare Corp (ticker: THC) on 08/28/2025 at a reported price of $183.44 per share. The Form 4 was signed by Chad J. Wiener as attorney-in-fact on 08/29/2025. The sale is reported as a direct disposition by the reporting person.
Lisa Y. Foo, Executive Vice President and Chief Operating Officer of Tenet Healthcare Corporation (THC), reported the sale of 8,000 shares of Tenet common stock on 08/20/2025 at a weighted average price of $179.53 per share. After the reported disposition, the reporting person beneficially owned 20,878 shares, held directly. The Form 4 was signed by an attorney-in-fact, Chad J. Wiener, on 08/22/2025. The filer indicates the aggregate sale included multiple transactions with prices ranging from $179.22 to $179.74, and offers to provide detailed per-transaction quantities on request.
Tenet Healthcare insider sale: Director Christopher S. Lynch sold 3,952 shares of Tenet Healthcare Corporation common stock on 08/19/2025 at a reported price of $176.39 per share, leaving him with 12,358 shares beneficially owned after the sale. The Form 4 was signed by an attorney-in-fact on 08/21/2025. The filing identifies Lynch as a director and the transaction is a direct sale of common stock.